NCT03563066 - Effect of Benralizumab in Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 4, 2018

Primary Completion Date

September 28, 2021

Study Completion Date

September 28, 2021

Conditions

Dermatitis, AtopicDermatitisEczemaSkin DiseasesSkin Diseases, GeneticGenetic Diseases, InbornSkin Diseases, EczematousHypersensitivityHypersensitivity, ImmediateImmune System Diseases

Interventions

DRUG

Benralizumab

Subcutaneous benralizumab injections once per month for 3 months on Days 0, 28 \& 56.

DRUG

Placebo Control

Subcutaneous placebo injections once per month for 3 months on Days 0, 28 \& 56.

Trial Locations (1)

L8N 3Z5

McMaster Cardio-Respiratory Research Lab, Hamilton